News ReleaseView printer-friendly version << Back
Pacira Announces New Data Supporting Clinical and Pharmacoeconomic Utility of EXPAREL in Patients Undergoing Various Surgical Procedures
The data presentation details and key findings are summarized below:
Liposomal Bupivacaine Improves Outcomes in Ileostomy Reversal Surgery and May Be Effective in More Complex Enhanced Recovery Procedures
- Forty-three patients undergoing loop ileostomy closure who received EXPAREL via subcutaneous and suprafascial infiltration had lower opioid consumption, pain scores, costs and shorter lengths of hospital stay compared to thirty-five patients who received bupivacaine HCl for postsurgical analgesia. Researchers hypothesize that EXPAREL may demonstrate similar outcomes in more complex surgeries if added to an enhanced recovery program. Read the full abstract here: http://link.springer.com/article/10.1007/s12630-015-0372-5
May 15, 2015 at
Comparative Study of Liposomal Bupivacaine versus Paravertebral Block for Pain Control Following Mastectomy with Immediate Tissue Expander Reconstruction
PSRC 60th Annual Meeting in
Lead Author: Jad M. Abdelsattar, MBBS;
- Patients who received local infiltration with EXPAREL (n=53) versus preoperative paravertebral block (n=44) for pain control following mastectomy with immediate tissue expander breast reconstruction reported lower pain scores, and required less opioids and antiemetic medication for nausea. Read the full abstract here: http://ps-rc.org/meeting/abstracts/2015/68.cgi
Evaluating Clinical and Economic Outcomes Associated with Liposomal Bupivacaine for Postsurgical Pain Following Total Knee Arthroplasty
ISPOR 20th Annual Meeting in
- More patients who received EXPAREL infiltration (n=134) compared to continuous nerve blocks via elastomeric pump (n=134) following knee replacement surgery were able to ambulate on the day of surgery and were discharged from the hospital in 3 days or less. Read the full abstract here: http://www.ispor.org/RESEARCH_STUDY_DIGEST/details.asp
“This collection of data reinforces the positive impact that EXPAREL
infiltration can make on both the patient recovery experience and
hospital economics,” said
EXPAREL is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The product combines bupivacaine with DepoFoam®, a proven product delivery technology that delivers medication over a desired time period. EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting. By utilizing the DepoFoam platform, a single dose of EXPAREL delivers bupivacaine over time, providing significant reductions in cumulative pain score with up to a 45 percent decrease in opioid consumption; the clinical benefit of the opioid reduction was not demonstrated. Additional information is available at www.EXPAREL.com.
Important Safety Information
EXPAREL is contraindicated in obstetrical paracervical block anesthesia. EXPAREL has not been studied for use in patients younger than 18 years of age. Non-bupivacaine-based local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from EXPAREL if administered together locally. The administration of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more. Other formulations of bupivacaine should not be administered within 96 hours following administration of EXPAREL. Monitoring of cardiovascular and neurological status, as well as vital signs should be performed during and after injection of EXPAREL as with other local anesthetic products. Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations. In clinical trials, the most common adverse reactions (incidence greater-than or equal to 10%) following EXPAREL administration were nausea, constipation, and vomiting.
Please see the full Prescribing Information for more details available at http://www.exparel.com/pdf/EXPAREL_Prescribing_Information.pdf.
Forward Looking Statements
Any statements in this press release about our future expectations,
plans, outlook and prospects, including statements about expected
non-GAAP product gross margins and operating expenses, and other
statements containing the words “believes,” “anticipates,” “plans,”
“estimates,” “expects,” and similar expressions, constitute
forward-looking statements within the meaning of
Pacira Pharmaceuticals, Inc.
Jessica Cho, 973-254-3574
Pure Communications, Inc.
Susan Heins, 864-286-9597